Filtered By:
Drug: Rituxan
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 5036 results found since Jan 2013.
Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study
CONCLUSION: Prophylactic TDF up to 6 months after completion of rituximab-based chemotherapy is sufficient in terms of the efficacy and safety of reducing HBV reactivation in patients with resolved HBV.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02585947.PMID:37463687 | PMC:PMC10353911 | DOI:10.3346/jkms.2023.38.e216
Source: J Korean Med Sci - July 18, 2023 Category: General Medicine Authors: Heejoon Jang Su Jong Yu Hong Ghi Lee Tae Min Kim Yun Bin Lee Eun Ju Cho Jeong-Hoon Lee Jung-Hwan Yoon Yoon Jun Kim Source Type: research
Efficacy and safety of novel biologics in the treatment of lupus nephritis based on registered clinical trials: a systematic review and network meta-analysis
This study protocol has been registered with PROSPERO, with a registration number of CRD42021262498.
Source: Clinical and Experimental Medicine - July 18, 2023 Category: Research Source Type: research
Immunochemotherapy or Chemotherapy Alone in Primary Central Nervous System Lymphoma, a National Cancer Data Base Analysis
We examined factors associated with receipt of immunotherapy using a multivariate regression for relative risk (RR), with random intercept to account for the hospital-specific treatment selection process. Patients were matched using a 1:1 propensity score to limit possible confounders and overall survival (OS) was compared in the matched cohort. We identified 4,691 patients with PCNSL diagnosed in 2013-2018. The use of immunotherapy increased from 45% in 2013 to 76% in 2018. Immunotherapy use was associated with sociodemographic variables and local (hospital-level) preference rather than clinical factors. The main factors ...
Source: Adv Data - July 17, 2023 Category: Epidemiology Authors: Thomas A Ollila Rashida Taher Prashanth Moku Adam J Olszewski Source Type: research
Low-grade B cell lymphoma in the perirenal space of the left kidney associated with high titer cold agglutinin disease
Am J Blood Res. 2023 Jun 15;13(3):104-109. eCollection 2023.ABSTRACTCold agglutinin disease (CAD) is a subgroup of autoimmune hemolytic anemia caused by monoclonal cold agglutinins produced by clonally expanded B lymphocytes. In primary CAD, lymphoproliferative bone marrow disorder is noted, while as one of the secondary cold agglutinin syndromes (CAS), the initial manifestation of CAD is followed by development of lymphoma. Here, we report a case of low-grade B cell lymphoma developed 3 months after an initial CAD diagnosis. The patient had an extremely high serum cold agglutinin titer (1:16,384) and slightly elevated ser...
Source: Cell Research - July 17, 2023 Category: Cytology Authors: Takashi Miyoshi Tomoya Masada Fumihiko Kono Shinsaku Imashuku Source Type: research
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Int J Clin Oncol. 2023 Jul 16. doi: 10.1007/s10147-023-02382-2. Online ahead of print.ABSTRACTCisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (...
Source: Clinical Breast Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Yuichi Ando Hiroyuki Nishiyama Hideki Shimodaira Nao Takano Emiko Sakaida Koji Matsumoto Koki Nakanishi Hideki Sakai Shokichi Tsukamoto Keigo Komine Yoshinari Yasuda Taigo Kato Yutaka Fujiwara Takafumi Koyama Hiroshi Kitamura Takashige Kuwabara Atsushi Yo Source Type: research
Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis
Clin Lymphoma Myeloma Leuk. 2023 Jun 26:S2152-2650(23)00196-9. doi: 10.1016/j.clml.2023.06.008. Online ahead of print.ABSTRACTPrimary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin's lymphoma involving the brain, cerebrospinal fluid, spinal cord and eyes. Rituximab has played a prominent role in the treatment of non-Hodgkin's B-cell lymphomas, including aggressive diffuse large B lymphoma. However, as a macromolecular drug, the role of rituximab in the treatment of PCNSL has been controversial. In this systematic review and meta-analysis, we evaluated the role of rituximab in the treatment of PCNSL. ...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Yuhang Zhang Zhihe Liu Chengwen Gao Haiyan Bian Yushuo Ma Fanjing Jing Xia Zhao Source Type: research
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Int J Clin Oncol. 2023 Jul 16. doi: 10.1007/s10147-023-02382-2. Online ahead of print.ABSTRACTCisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (...
Source: Clinical Breast Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Yuichi Ando Hiroyuki Nishiyama Hideki Shimodaira Nao Takano Emiko Sakaida Koji Matsumoto Koki Nakanishi Hideki Sakai Shokichi Tsukamoto Keigo Komine Yoshinari Yasuda Taigo Kato Yutaka Fujiwara Takafumi Koyama Hiroshi Kitamura Takashige Kuwabara Atsushi Yo Source Type: research
Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis
Clin Lymphoma Myeloma Leuk. 2023 Jun 26:S2152-2650(23)00196-9. doi: 10.1016/j.clml.2023.06.008. Online ahead of print.ABSTRACTPrimary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin's lymphoma involving the brain, cerebrospinal fluid, spinal cord and eyes. Rituximab has played a prominent role in the treatment of non-Hodgkin's B-cell lymphomas, including aggressive diffuse large B lymphoma. However, as a macromolecular drug, the role of rituximab in the treatment of PCNSL has been controversial. In this systematic review and meta-analysis, we evaluated the role of rituximab in the treatment of PCNSL. ...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Yuhang Zhang Zhihe Liu Chengwen Gao Haiyan Bian Yushuo Ma Fanjing Jing Xia Zhao Source Type: research
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Int J Clin Oncol. 2023 Jul 16. doi: 10.1007/s10147-023-02382-2. Online ahead of print.ABSTRACTCisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (...
Source: Clinical Genitourinary Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Yuichi Ando Hiroyuki Nishiyama Hideki Shimodaira Nao Takano Emiko Sakaida Koji Matsumoto Koki Nakanishi Hideki Sakai Shokichi Tsukamoto Keigo Komine Yoshinari Yasuda Taigo Kato Yutaka Fujiwara Takafumi Koyama Hiroshi Kitamura Takashige Kuwabara Atsushi Yo Source Type: research
Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis
Clin Lymphoma Myeloma Leuk. 2023 Jun 26:S2152-2650(23)00196-9. doi: 10.1016/j.clml.2023.06.008. Online ahead of print.ABSTRACTPrimary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin's lymphoma involving the brain, cerebrospinal fluid, spinal cord and eyes. Rituximab has played a prominent role in the treatment of non-Hodgkin's B-cell lymphomas, including aggressive diffuse large B lymphoma. However, as a macromolecular drug, the role of rituximab in the treatment of PCNSL has been controversial. In this systematic review and meta-analysis, we evaluated the role of rituximab in the treatment of PCNSL. ...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Yuhang Zhang Zhihe Liu Chengwen Gao Haiyan Bian Yushuo Ma Fanjing Jing Xia Zhao Source Type: research
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Int J Clin Oncol. 2023 Jul 16. doi: 10.1007/s10147-023-02382-2. Online ahead of print.ABSTRACTCisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (...
Source: Clinical Genitourinary Cancer - July 15, 2023 Category: Cancer & Oncology Authors: Yuichi Ando Hiroyuki Nishiyama Hideki Shimodaira Nao Takano Emiko Sakaida Koji Matsumoto Koki Nakanishi Hideki Sakai Shokichi Tsukamoto Keigo Komine Yoshinari Yasuda Taigo Kato Yutaka Fujiwara Takafumi Koyama Hiroshi Kitamura Takashige Kuwabara Atsushi Yo Source Type: research
Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis
Clin Lymphoma Myeloma Leuk. 2023 Jun 26:S2152-2650(23)00196-9. doi: 10.1016/j.clml.2023.06.008. Online ahead of print.ABSTRACTPrimary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin's lymphoma involving the brain, cerebrospinal fluid, spinal cord and eyes. Rituximab has played a prominent role in the treatment of non-Hodgkin's B-cell lymphomas, including aggressive diffuse large B lymphoma. However, as a macromolecular drug, the role of rituximab in the treatment of PCNSL has been controversial. In this systematic review and meta-analysis, we evaluated the role of rituximab in the treatment of PCNSL. ...
Source: Clinical Lymphoma and Myeloma - July 15, 2023 Category: Cancer & Oncology Authors: Yuhang Zhang Zhihe Liu Chengwen Gao Haiyan Bian Yushuo Ma Fanjing Jing Xia Zhao Source Type: research
